Human epidermal growth factor receptor 2 (HER2), a key protagonist in breast cancer development, plays a pivotal role, particularly in HER2-positive breast cancer—a malignancy afflicting 20% to 30% of breast cancer cases.[6] Known for their aggressive nature and grim prognostic outlook, HER2-positive breast cancers pose a considerable threat, with 20% to 30% of patients facing recurrence.[7]. Here, ERBB2 is linked to breast carcinoma.